Pieris Pharmaceuticals Stock Today
| PIRS Stock | USD 15.93 0.08 0.50% |
Performance0 of 100
| Odds Of DistressOver 81
|
Pieris Pharmaceuticals is selling for under 15.93 as of the 21st of November 2024; that is 0.5 percent decrease since the beginning of the trading day. The stock's lowest day price was 15.39. Pieris Pharmaceuticals has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Pieris Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 2nd of December 2022 and ending today, the 21st of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 13th of April 2015 | Category Healthcare | Classification Health Care |
Pieris Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs. Pieris Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Boston, Massachusetts. Pieris Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 1.32 M outstanding shares of which 22.5 K shares are at this time shorted by private and institutional investors with about 3.52 trading days to cover. More on Pieris Pharmaceuticals
Moving together with Pieris Stock
Moving against Pieris Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Pieris Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Stephen JD | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsPieris Pharmaceuticals can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Pieris Pharmaceuticals' financial leverage. It provides some insight into what part of Pieris Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Pieris Pharmaceuticals (PIRS) is traded on NASDAQ Exchange in USA. It is located in 225 Franklin Street, Boston, MA, United States, 02110 and employs 46 people. Pieris Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 21.14 M. Pieris Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.32 M outstanding shares of which 22.5 K shares are at this time shorted by private and institutional investors with about 3.52 trading days to cover.
Pieris Pharmaceuticals currently holds about 80.94 M in cash with (53.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.09.
Check Pieris Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Pieris Pharmaceuticals is $21.14 Million. Over half of Pieris Pharmaceuticals' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Pieris Ownership Details
Pieris Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2024-06-30 | 164 | |
| U.s. Bancorp | 2024-06-30 | 158 | |
| Barclays Plc | 2024-06-30 | 63.0 | |
| Wells Fargo & Co | 2024-06-30 | 60.0 | |
| Jpmorgan Chase & Co | 2024-06-30 | 27.0 | |
| Bank Of America Corp | 2024-06-30 | 13.0 | |
| Advisor Group Holdings, Inc. | 2024-06-30 | 7.0 | |
| Hanson Mcclain Inc | 2024-09-30 | 5.0 | |
| Royal Bank Of Canada | 2024-06-30 | 4.0 | |
| Bvf Inc | 2024-09-30 | 257.6 K | |
| Bml Capital Management Llc | 2024-09-30 | 42.1 K |
Pieris Pharmaceuticals Historical Income Statement
Pieris Stock Against Markets
Pieris Pharmaceuticals Corporate Management
| Florian Witte | VP Leadership | Profile | |
| Maria Kelman | Executive Relations | Profile | |
| Prompong Chaikul | Chief Officer | Profile | |
| Ahmed JD | Chief VP | Profile | |
| Gordon MD | Head Oncology | Profile |
Additional Tools for Pieris Stock Analysis
When running Pieris Pharmaceuticals' price analysis, check to measure Pieris Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pieris Pharmaceuticals is operating at the current time. Most of Pieris Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pieris Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pieris Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pieris Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.